316 related articles for article (PubMed ID: 19884278)
1. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
[TBL] [Abstract][Full Text] [Related]
2. IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
Rheumatology (Oxford); 2008 Oct; 47(10):1489-92. PubMed ID: 18703528
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
[TBL] [Abstract][Full Text] [Related]
5. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
[TBL] [Abstract][Full Text] [Related]
6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
8. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
10. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles.
Snir O; Widhe M; von Spee C; Lindberg J; Padyukov L; Lundberg K; Engström A; Venables PJ; Lundeberg J; Holmdahl R; Klareskog L; Malmström V
Ann Rheum Dis; 2009 May; 68(5):736-43. PubMed ID: 18635594
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
12. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis.
Bang H; Egerer K; Gauliard A; Lüthke K; Rudolph PE; Fredenhagen G; Berg W; Feist E; Burmester GR
Arthritis Rheum; 2007 Aug; 56(8):2503-11. PubMed ID: 17665451
[TBL] [Abstract][Full Text] [Related]
13. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
Greiner A; Plischke H; Kellner H; Gruber R
Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
15. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities.
Ioan-Facsinay A; el-Bannoudi H; Scherer HU; van der Woude D; Ménard HA; Lora M; Trouw LA; Huizinga TW; Toes RE
Ann Rheum Dis; 2011 Jan; 70(1):188-93. PubMed ID: 20736390
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort.
Nicaise-Roland P; Nogueira L; Demattei C; de Chaisemartin L; Rincheval N; Cornillet M; Grootenboer-Mignot S; Dieudé P; Dougados M; Cantagrel A; Meyer O; Serre G; Chollet-Martin S
Ann Rheum Dis; 2013 Mar; 72(3):357-62. PubMed ID: 22580581
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
19. The role of anti-mutated citrullinated vimentin antibodies in the diagnosis of early rheumatoid arthritis.
Liu X; Jia R; Zhao J; Li Z
J Rheumatol; 2009 Jun; 36(6):1136-42. PubMed ID: 19447936
[TBL] [Abstract][Full Text] [Related]
20. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
